About
History
Niowave: Two Decades of Innovation
2005-2009
Foundation Of A Superconducting Accelerator Platform
Niowave founded; superconducting linac platform built and deployed for national security, research, and early isotope applications while supporting government and national lab customers.
2010-2014
First-In-World Technology Leadership
Achieved multiple accelerator milestones establishing world leadership in the field and secured NRC licensing, establishing unique infrastructure and regulatory capability.
2015-2019
Strategic Pivot
To Radioisotopes
Narrowed focus to radioisotope production; launched Mo-99 and Ac-225 development with U.S. government selection, funding, and expanded radiochemistry capabilities.
2020-2022
Securing Supply And
Establishing Quality
Transitioned to commercial isotope supply with Ac-225 and Y-90 programs, ISO 13485 quality systems. Delivered 1st sample non GMP; 24/7 linac operations; Ac-225 radiochemistry program expansion.
2023-Present
Leading Industry In Ac-225 Production
Scaling Ac-225 production with new facilities; FDA DMF acceptance; expanded NRC licenses; increased radium inventory to support long-term commercial supply.
The Next Chapter
Learn about our newest facility, currently under development, and how it represents the next chapter of Niowave.